Explore how the QPS imiquimod-induced psoriasis model and wound-healing research capabilities can help inform drug treatment development. Then catch up on the latest scientific insights from the QPS blog.
Get a clearer picture of your psoriasis candidate’s potential before making your next development decision.
QPS uses the imiquimod (IMQ)-induced psoriasis model to assess your test article’s therapeutic effects and generate preclinical data to guide future development decisions.
Understand how your test article affects wound healing before planning your next study. QPS’ in vivo models track recovery and healing after surgical procedures, with histopathology findings to help you interpret the results and decide what comes next.
All studies undergo IACUC review and follow animal welfare requirements.
As patents expire on biological drugs over the next decade, opportunities for biosimilar development should be growing. The pipeline tells a different story…
Drug approval has long been associated with two identical pivotal clinical trials demonstrating that not only is the drug safe and effective, but also that the…
Request a meeting with QPS preclinical, bioanalysis, translational medicine, and/or clinical research subject matter experts today to explore how we can help accelerate your next drug development program.
We use your email address exclusively for sending QPS newsletters with a special e-mail program. If you no longer wish to receive any mailings, simply use the "unsubscribe" link at the bottom. If you don't unsubscribe, we assume that this consent also applies to the system of the GDPR. (Data protection notice: According to Art. 7 GDPR, the consent can of course also be withdrawn at any time after May 25, 2018.)
QPS Holdings, LLC | Three Innovation Way | Newark , DE 19711 US
